New Treatments for Heart Failure with Reduced Ejection Fraction
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
Recruiting
Observational Study
Heart Failure With Reduced Ejection Fraction
Pulmonary Hypertension
Right Heart Failure Due to Left Heart Failure
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 90
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50 (estimated)
- Sponsor
- Johns Hopkins University · Other
Who this trial is looking for
This trial is looking for adults with heart failure and related conditions. Participants will help researchers find ways to better understand and treat heart issues.
Are You a Good Fit for This Trial?
You may be able to join if
- I am between 18 and 90 years old
- I have heart failure with reduced ejection fraction
- I can safely stop taking anticoagulant medication for 48 hours before the procedure
You may not be able to join if
- I cannot stop taking anticoagulant medication
- My INR level is over 1.5
- I am pregnant
- I have been hospitalized or had worsening symptoms in the last 2 weeks
- I participated in another trial with an investigational drug in the last 4 weeks
- I cannot lie flat on my back
- I have unstable symptoms at rest or during the procedure
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify u…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult patients aged between 18 and 90 years of age
* Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40-50%)
* Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure
Exclusion Criteri…
Contacts